Refine by
Allergy Sufferer Articles & Analysis
37 news found
Asthma and Allergy Awareness Month is just a few weeks away, and this year, the 6th of May is recognized as World Asthma Day. ...
For many, their pet is a part of the family, but unfortunately, many homes with pets also suffer from indoor environmental quality (IEQ) issues associated with pet odors and allergens. ...
Fortunately for many of us, and unfortunately for many others, it means flowers will be in bloom after spring rains and some of us will be suffering with seasonal allergic rhinitis, more commonly referred to as hay fever. ...
Mold spores also contribute to spring allergies but are typically more bothersome in the autumn months. There is limited cross-reactivity between tree pollens. ...
PGIMER has acquired this very specialised equipment which will be a boon for all patients of kidney disease, diabetes and contrast allergies, who normally suffer delay in angiographic procedures like angioplasties and stenting due to risk of iodinated contrast toxicity. ...
Food Allergy Research and Education (FARE) has established that more than 32 million people in the US are victims of food allergy. Almost 8% of children with a food allergy are less than 5 years old and overall 4% of adults suffer from food allergies. ...
The agency reports that 1 in 13 Americans (more than 25 million) lives with the condition. Add allergies to the equation and the Asthma and Allergy Foundation of America states that over 65 million Americans are affected. ...
Unlike COVID-19, seasonal allergies aren't caused by a virus. Seasonal allergies are immune system responses triggered by exposure to allergens, such as seasonal tree or grass pollens. To complicate the situation, allergy sufferers are experiencing longer allergy seasons, earlier onset, and there is just more ...
NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced that its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy has been amended to allow ...
” The Company’s oral mucosal immunotherapy (OMIT) platform is based on the well-accepted principles of allergy immunotherapy. The company’s initial product, INT301, is an immunotherapy treatment for peanut allergy delivered via a specially-formulated toothpaste designed to optimize exposure of allergenic proteins to a patient’s immune ...
“Angany’s approach should bring hope to the millions of people affected by respiratory and food allergy. We are looking forward to communicating with US allergists on how this innovative form of allergy immunotherapy may soon help them provide better options for people faced with allergy,” states Dr. ...
The product delivers allergenic proteins to areas of the oral cavity to naturally trigger an immune system response towards tolerance of the allergen. “As a peanut allergy sufferer myself, I am driven to help reduce fear around peanut allergies for patients and families everywhere,” said William Reisacher, M.D., Senior Scientific ...
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced today that it will be presenting at BIO Digital 2021. ...
” A survey conducted April 28, 2020 by Advanced Data Management (ADM) on behalf of Allovate found that 95% of physicians who responded (including allergists, otolaryngologists, and other physicians who treat patients with allergies) were having difficulty providing treatment to their patients suffering from respiratory allergies. ...
OMIT enables regular administration of allergy immunotherapy to desensitize a patient to allergies while a user brushes their teeth. ...
Employees that go to work or tenants that arrive home, and develop allergy symptoms that improve or go away once they leave the building, could very likely be having an allergic reaction to indoor environmental allergens. ...
The corporation in Bilbao is leading in the sector of specific immunotherapy and allergy investigation, one of their focuses being the investigation of recombinant allergens. ...
For people who suffer from allergies, a visit to their doctor’s office for a consultation and treatment options is a common occurrence. People often look for medical treatment that can alleviate their allergy symptoms without considering what allergens may be causing their condition in the first place. ...
Allovate is licensing the rights to develop the OMIT platform for the treatment of food allergies to Intrommune Therapeutics, which will focus initially on an FDA-approved treatment for peanut allergy. ...
For most people, the majority of their time is spent at home and at their place of business. For those with allergies, both of these indoor environments can often be a source of allergens that cause or aggravate their condition. ...